Menu
Search
|

Menu

Close
X

Dare Bioscience Inc DARE.OQ (NASDAQ Stock Exchange Capital Market)

0.94 USD
-0.01 (-1.00%)
As of 3:09 PM GMT
chart
Previous Close 0.95
Open 0.95
Volume 884
3m Avg Volume 25,049
Today’s High 0.95
Today’s Low 0.94
52 Week High 3.58
52 Week Low 0.75
Shares Outstanding (mil) 6.05
Market Capitalization (mil) 19.23
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 2 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-1.422
FY17
-2.645
FY16
-9.165
FY15
-15.630
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.59
Price to Sales (TTM)
vs sector
7.40
5.69
Price to Book (MRQ)
vs sector
2.27
5.11
Price to Cash Flow (TTM)
vs sector
--
23.52
Total Debt to Equity (MRQ)
vs sector
0.00
15.71
LT Debt to Equity (MRQ)
vs sector
0.00
11.53
Return on Investment (TTM)
vs sector
-126.16
15.05
Return on Equity (TTM)
vs sector
-169.76
16.62

EXECUTIVE LEADERSHIP

Roger Hawley
Independent Chairman of the Board, Since 2017
Salary: --
Bonus: --
Sabrina Johnson
President, Chief Executive Officer, Secretary, Director, Since 2017
Salary: --
Bonus: --
Gregg Beloff
Principal Financial Officer, Since 2017
Salary: --
Bonus: --
Lisa Walters-Hoffert
Chief Financial Officer, Since 2017
Salary: --
Bonus: --
Jame O'Neill
Principal Accounting Officer, Controller, Assistant Treasurer, Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

3655 Nobel Dr Ste 260
SAN DIEGO   CA   92122-1050

Phone: +1858.9267655

Dare Bioscience, Inc., formerly Cerulean Pharma Inc., is a healthcare company. The Company is focused on the development and commercialization of products in women’s reproductive health. Its lead product candidate is Ovaprene, a clinical stage, non-hormonal contraceptive ring. The Company is developing Ovaprene to provide protection over multiple weeks of use and require no intervention at the time of intercourse. Ovaprene has a custom intravaginal ring design, with a permeable mesh in the center of the ring that creates a partial barrier to sperm, and a mechanism to release locally acting spermiostatic agents through the ring. The combination of these two complementary approaches produces attractive contraceptive efficacy outcomes that are consistent with the effective barrier option, the diaphragm, and short-acting hormonal options, such as oral pill, patches and vaginal ring.

SPONSORED STORIES